Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt’s lymphoma with TP53 mutations

Burkitt’s lymphoma (BL) with TP53 mutation often has poor outcome after standard chemoimmunotherapy. Adoptive chimeric antigen receptor (CAR)-T cell therapy may be a new paradigm for treating refractory/relapsed (r/r) BL, but its therapeutic effects remain inconclusive. Here, we report a patient wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qi, Zhu, Xiaojian, Liu, Bo, Zhang, Yicheng, Xiao, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063779/
https://www.ncbi.nlm.nih.gov/pubmed/37006273
http://dx.doi.org/10.3389/fimmu.2023.1127868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063779/
https://www.ncbi.nlm.nih.gov/pubmed/37006273
http://dx.doi.org/10.3389/fimmu.2023.1127868

Ejemplares similares